Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Pacific Edge Limited ( (PFGTF) ).
Pacific Edge Limited, a leader in bladder cancer diagnostics, has released its annual report for the year ended 31 March 2025. The report highlights the company’s continued focus on expanding its global reach and enhancing its diagnostic capabilities, which are crucial for patients with hematuria and for monitoring recurrent bladder cancer. This strategic positioning is expected to strengthen its market presence and provide significant benefits to stakeholders.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. The company is headquartered in Dunedin, New Zealand, and is listed on the NZX and the ASX under the ticker code PEB. It provides its Cxbladder tests globally through its CLIA certified laboratories in New Zealand and the USA.
See more insights into PFGTF stock on TipRanks’ Stock Analysis page.